


HUMAN NAMkind™ MASH

Does your MASH therapy deliver?



Evaluate anti-fibrotic activity in patient-derived human liver disease tissue.

Patient-derived

Human disease tissue

Disease-relevant biology

14-21 days

Repeat dosing

Follow the tissue response

Same-donor


Study controls

Benchmark treatment effects

Connect disease biology to response with tissue health measured alongside efficacy.

Human biology at the center of your study.

3D HUMAN LIVER TISSUE



96-well format

MASH in 3D

Steatotic, fibrogenic human liver tissue with collagen deposition.

Fibrogenesis	P1NP
Collagen	PSR staining
Liver function	Albumin

Schematic illustration; not to scale.

Which candidate should move forward?

Compare dose-dependent anti-fibrotic responses alongside viability and liver function.

Bring your MASH program.

Ask our team about your next study.

DETAILS ON REVERSE



HUMAN NAMkind™ MASH

Measure efficacy. Resolve the tissue response.

Combine disease-relevant readouts with tissue health.

Standard endpoint panel

INCLUDED

ASSAY	WHAT IT MEASURES
Albumin	Hepatocyte function
ATP	Tissue viability
GSH	Cellular glutathione status
LDH	Cytotoxicity / tissue injury
P1NP	Fibrogenesis
Picrosirius Red (PSR) staining	Collagen deposition

Go deeper with custom assays

ADDITIONAL FEE

- Immunohistochemistry
- Soluble fibrogenic biomarkers
- RNAseq

Desired antigens
ProC3, P3NP
Transcriptomic profiling

Build a study around your next decision.

01 / QUESTION

Anti-fibrotic activity

02 / STUDY DESIGN

Donor tissue, dosing, controls

03 / READOUTS

Standard + custom assays

Let's design your efficacy study.

contact@vivosim.ai

vivosim.ai

SCAN TO
EMAIL US

